Cargando…

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

AIMS: To assess fesoterodine 8 mg efficacy over time and vs. placebo in subjects with overactive bladder (OAB) who responded suboptimally to tolterodine extended release (ER) 4 mg. METHODS: In a 12-week, double-blind trial, subjects with self-reported OAB symptoms for ≥ 6 months, mean of ≥ 8 micturi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaplan, S A, Cardozo, L, Herschorn, S, Grenabo, L, Carlsson, M, Arumi, D, Crook, T J, Whelan, L, Scholfield, D, Ntanios, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265241/ https://www.ncbi.nlm.nih.gov/pubmed/24898471 http://dx.doi.org/10.1111/ijcp.12464

Ejemplares similares

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study
por: Wyndaele, J-J, et al.
Publicado: (2009)

Tolterodine extended release is well tolerated in older subjects
por: Griebling, T L, et al.
Publicado: (2009)

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study
por: Castro-Diaz, David, et al.
Publicado: (2012)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Protocol for a phase II, open-label exploratory study investigating the efficacy of fesoterodine for treatment of adult patients with spinal cord injury suffering from neurogenic detrusor overactivity for amelioration of autonomic dysreflexia
por: Walter, Matthias, et al.
Publicado: (2018)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

Role of fesoterodine in the treatment of overactive bladder
por: Mansfield, Kylie J
Publicado: (2009)

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine
por: Wagg, Adrian S., et al.
Publicado: (2021)

Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2010)

Efficacy of tolterodine in children with overactive bladder
por: Koç, Başak, et al.
Publicado: (2020)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine
por: Wyndaele, Jean-Jacques
Publicado: (2012)

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)
por: Drake, Marcus J., et al.
Publicado: (2017)

Update on tolterodine extended-release for treatment of overactive bladder
por: Omotosho, Tola, et al.
Publicado: (2010)

Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder
por: Heesakkers, John, et al.
Publicado: (2022)

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
por: Nitti, V W, et al.
Publicado: (2013)

Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder
por: Rajabalaya, Rajan, et al.
Publicado: (2016)

Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence
por: Wyman, J F, et al.
Publicado: (2009)

Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder
por: Lee, L. K., et al.
Publicado: (2015)

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
por: Ulahannan, Danny, et al.
Publicado: (2009)

Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women
por: Aziminekoo, Elham, et al.
Publicado: (2014)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018)

Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
por: Morris, Vikky, et al.
Publicado: (2014)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
por: Staskin, David, et al.
Publicado: (2017)

Risk factors associated with the progression of overactive bladder among patients with type 2 diabetes
por: Zhu, Yiyi, et al.
Publicado: (2019)

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function
por: Zachariou, Athanasios, et al.
Publicado: (2017)

NGF and HB-EGF: Potential Biomarkers that Reflect the Effects of Fesoterodine in Patients with Overactive Bladder Syndrome
por: Kim, Soo Rim, et al.
Publicado: (2015)

Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?
por: Heesakkers, John, et al.
Publicado: (2017)

Impact of depression on overactive bladder
por: Kawahara, Takashi, et al.
Publicado: (2020)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial
por: Xiao, Dong-dong, et al.
Publicado: (2016)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017)

Effects of Bladder Training and/or Tolterodine in Female Patients with Overactive Bladder Syndrome: A Prospective, Randomized Study
por: Song, Cheryn, et al.
Publicado: (2006)

Dissimilar Effects of Tolterodine on Detrusor Overactivity in Awake Rats with Chemical Cystitis and Partial Bladder Outlet Obstruction
por: Jin, Long-Hu, et al.
Publicado: (2011)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fsno2oda3djb5sag59lsv1rrg6